Skip to main content
SpringerLink
Log in

Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease

  • Original Articles
  • Pt Complexes Clearances
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

The blood clearances of three platinum compounds, cis-dichlorodiammine platinum II (DDP), cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV (CHIP), and cis-dichloro-bis-cyclopropylamine platinum II (CP), were determined in nine patients with malignant disease. The complexes were prepared using radioactive platinum (191Pt and 193Pt). A 10-μCi dose of each complex, containing the equivalent of 1–2 mg elemental platinum, was injected IV into groups of three patients. Serial blood and urine samples were collected over 72 h.

No obvious difference was found between the three complexes for blood clearance, median t1/2α being 16.8 (range 11.2–23.5) min and median t1/2β 89 (range 63.7–127) h. The urinary excretion was greatest for CHIP, 60% of injected dose as against 42.6% for CP and 38.8% for DDP.

Differences in renal excretion of DDP analogues could indicate potentially less nephrotoxic agents. The use of radioactive Pt will allow in vivo dynamic imaging of the distribution of platinum compounds in areas of interest.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Crom WR, Evans WE, Pratt CB, Senzer N, Denison M, Green AA, Hayes FA, Yee GC (1981) cis-Platin disposition in children and adolescents with cancer. Cancer Chemother Pharmacol 6: 95–99

    Google Scholar 

  2. DeConti RC, Toftness BR, Lange RC, Creasey WA (1973) Clinical and pharmacological studies with cis-dichlorodiammino platinum (II). Cancer Res 33: 1310–1315

    Google Scholar 

  3. Einhorn LH, Williams SD (1979) The role of cis-platinum in solid-tumour therapy. N Engl J Med 300: 289–291

    Google Scholar 

  4. Frick GA, Ballentine R, Driever CW, et al. (1979) Renal excretion kinetics of high-dose cis-dichloro-diammine platinum (II) administered with hydration and mannitol diuresis. Cancer Treat Rep 63: 13–16

    Google Scholar 

  5. Gormley PE, Bull JM, LeRoy AF, Cysyk R (1979) Kinetics of cis-dichlorodiammino platinum. Clin Pharmacol Ther 25:351–357

    Google Scholar 

  6. Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF, Woolley PV (1980) Binding of cis-dichlorodiammine platinum (II) administered as a one-hour or as a twenty-hour infusion. Cancer Chemother Pharmacol 5: 21–26

    Google Scholar 

  7. Harrap KR, Jones M, Wilkinson CR, Clink H McD, Sparrow S, Mitchley BCV, Clarke S, Veasey A (1980) Antitumour, toxic and biochemical properties of cis-platin and eight other platinum complexes. In: Prestayko AW, Crooke ST, Carter SK (eds) cis-Platin: Current status and new developments Academic Press, New York London Toronto Sydney San Francisco, pp 193–212

    Google Scholar 

  8. Prestayko AW, D'Aoust JC, Issell BF, Cooke ST (1979) cis Platin (cis-diammine dichloroplatinum II). Cancer Treat Rev 6: 17–39

    Google Scholar 

  9. Sharma HL, Smith AG (1981) The short-lived radioisotope production program at Manchester. J Radioanal Chem 64:249–255

    Google Scholar 

  10. Wolf N, Manaka RC, Leh FKU (1978) The use of radionuclides of platinum. J Clin Hematol Oncol 7: 741–759

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Christie Hospital, Wilmslow Road, M20 9BX, Manchester

    N. Thatcher & D. Crowther

  2. Holt Radium Institute, Wilmslow Road, M20 9BX, Manchester

    N. Thatcher & B. W. Fox

  3. Department of Medical Biophysics, University of Manchester, Medical School, M20 9BX, Manchester

    H. Sharma & A. Smith

  4. Radiochemical Center, Amersham International, Bucks

    R. Harrison

  5. Department of Inorganic Chemistry, University of Manchester Institute of Science and Technology, M20 9BX, Manchester

    A. Zaki & C. A. McAuliffe

  6. Paterson Laboratories, Christie Hospital, Wilmslow Road, M20 9BX, Manchester, Great Britain

    B. W. Fox

Authors
  1. N. Thatcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Zaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. A. McAuliffe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Crowther
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. W. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thatcher, N., Sharma, H., Harrison, R. et al. Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease. Cancer Chemother. Pharmacol. 9, 13–16 (1982). https://doi.org/10.1007/BF00296754

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00296754

Keywords

Search

Navigation